ReviewJournal of proteome research2020
Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease.
Review in Journal of proteome research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 81 citations in OpenAlex.
- Beyond ALT flares: rethinking immune activation and mechanistic interpretation in bepirovirsen-treated chronic hepatitis B.Hepatology international · 2026Article
- Article
- The dark matter in cancer immunology: beyond the visible- unveiling multiomics pathways to breakthrough therapies.Journal of translational medicine · 2025Review
- What Can Proteomics Tell us About COVID-19 Infections? Mass Spectrometry as a Tool to Find New Proteins as Biomarkers.Current protein & peptide science · 2025Review
- Post COVID-19 complications and follow up biomarkers.Nanoscale advances · 2023Review
- COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine.Reports (MDPI) · 2023Review
- Flow Cytometry: The Next Revolution.Cells · 2023Review
- Feasibility of detecting snake envenomation biomarkers from dried blood spots.Analytical science advances · 2023Article
- Peripheral Blood Genes Crosstalk between COVID-19 and Sepsis.International journal of molecular sciences · 2023Article
- Inflammation in COVID-19 and the Effects of Non-Pharmacological Interventions during the Pandemic: A Review.International journal of molecular sciences · 2022Review
- Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer.ACS applied materials & interfaces · 2022Article
- Host and viral proteins involved in SARS-CoV-2 infection differentially bind heme.Protein science : a publication of the Protein Society · 2022Article
- SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death.Medical sciences (Basel, Switzerland) · 2022Review
- A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action.Proteomics · 2022Review
- Proteomics research of SARS-CoV-2 and COVID-19 disease.Medical review (2021) · 2022Review
- DNA-Based Biosensors for the Biochemical Analysis: A Review.Biosensors · 2022Review
- Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission.Scientific reports · 2022Article
- Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.Gastro hep advances · 2022Article
- Identification of SARS-CoV-2 Proteins from Nasopharyngeal Swabs Probed by Multiple Reaction Monitoring Tandem Mass Spectrometry.ACS omega · 2021Article
- International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests.Journal of thrombosis and thrombolysis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The emergence of novel coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 coronavirus, has necessitated the urgent development of new diagnostic and therapeutic strategies. Rapid research and development, on an international scale, has already generated assays for detecting SARS-CoV-2 RNA and host immunoglobulins. However, the complexities of COVID-19 are such that fuller definitions of patient status, trajectory, sequelae, and responses to therapy are now required. There is accumulating evidence-from studies of both COVID-19 and the related disease SARS-that protein biomarkers could help to provide this definition. Proteins associated with blood coagulation (D-dimer), cell damage (lactate dehydrogenase), and the inflammatory response (e.g., C-reactive protein) have already been identified as possible predictors of COVID-19 severity or mortality. Proteomics technologies, with their ability to detect many proteins per analysis, have begun to extend these early findings. To be effective, proteomics strategies must include not only methods for comprehensive data acquisition (e.g., using mass spectrometry) but also informatics approaches via which to derive actionable information from large data sets. Here we review applications of proteomics to COVID-19 and SARS and outline how pipelines involving technologies such as artificial intelligence could be of value for research on these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.